NIH study revises molecular classification for most common type of lymphoma | National Institutes of Health (NIH)
Trial results show that younger lymphoma patients respond well to ibrutinib | Center for Cancer Research
Overall survival following Richter transformation on ibrutinib by line... | Download Scientific Diagram
Diffuse Large B-Cell Lymphoma | NEJM
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology
JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies | Cell Death & Disease
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma | Annals of Hematology
The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
Cancers | Free Full-Text | Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Ibrutinib improves survival in young people with diffuse large B-cell lymphoma
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma | Journal of Experimental & Clinical Cancer Research | Full Text
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma | Nature Medicine
Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. | Semantic Scholar
JCI - Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study - The Lancet Healthy Longevity
Treatment resistance in diffuse large B-cell lymphoma | Leukemia
